Literature DB >> 9559823

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).

J E Hoppe1, A Bryskier.   

Abstract

When tested by agar dilution on Mueller-Hinton agar supplemented with 5% horse blood, the ketolides HMR 3004 and HMR 3647 were slightly more active (MIC at which 90% of the isolates were inhibited [MIC90], 0.03 microg/ml) against Bordetella pertussis than azithromycin, clarithromycin, erythromycin A, and roxithromycin. Azithromycin (MIC90, 0.06 microg/ml) was the most active compound against B. parapertussis. Rifampin and rifapentine were considerably less active.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559823      PMCID: PMC105582          DOI: 10.1128/AAC.42.4.965

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; A Eichhorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 2.  Antimicrobial susceptibility of Bordetella pertussis (Part I).

Authors:  J E Hoppe; A Haug
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

3.  In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

Authors:  T Schülin; C B Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; T Tschirner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

5.  Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981.

Authors:  R M Bannatyne; R Cheung
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Antimicrobial activity of RU-66647, a new ketolide.

Authors:  R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

8.  Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin.

Authors:  G Zackrisson; J E Brorson; B Björnegård; B Trollfors
Journal:  J Antimicrob Chemother       Date:  1985-05       Impact factor: 5.790

9.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

  9 in total
  6 in total

1.  In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

3.  Widespread Bordetella parapertussis Infections-Wisconsin, 2011-2012: Clinical and Epidemiologic Features and Antibiotic Use for Treatment and Prevention.

Authors:  Ruth Koepke; Michael L Bartholomew; Jens C Eickhoff; Roman A Ayele; Diane Rodd; Joan Kuennen; Jean Rosekrans; David M Warshauer; James H Conway; Jeffrey P Davis
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

Review 4.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

6.  The First Macrolide-Resistant Bordetella pertussis Strains Isolated From Iranian Patients.

Authors:  Fereshteh Shahcheraghi; Masoumeh Nakhost Lotfi; Vajiheh Sadat Nikbin; Fahimeh Shooraj; Reza Azizian; Masoumeh Parzadeh; Mohammad Reza Allahyar Torkaman; Seyed Mohsen Zahraei
Journal:  Jundishapur J Microbiol       Date:  2014-06-01       Impact factor: 0.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.